title: Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of a loading regimen of the anti-tumour necrosis factor alpha (TNF-alpha) antibody infliximab in predominantly axial severe ankylosing spondylitis (AS).
  
  
  METHODS
  We enrolled in this study 50 patients (76% males, 87% HLA-B27(+), median age 35 yr, median disease duration 13 yr) with active AS [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >or=30/100 and serum C-reactive protein concentration >or=15 mg/l) despite treatment with a non-steroidal anti-inflammatory drug, and without peripheral arthritis, uveitis or active inflammatory bowel disease. Other disease-modifying anti-rheumatic drugs were discontinued >or=3 months before inclusion and were not allowed during the study. Patients received three infusions of infliximab (5 mg/kg) at weeks 0, 2 and 6 and were monitored clinically and biologically until week 24.
  
  
  RESULTS
  Forty-eight patients completed the treatment. In intention-to-treat analysis, all parameters were significantly improved at week 2 and generally reached maximal improvement at week 8. The proportion of responders, defined by a reduction of >or=20% in the global assessment of pain (GAP) or by the AS Assessment Study Group (ASAS 20%) criteria, and the proportion of patients reaching partial remission were 98, 94 and 70% respectively. Relapse, defined as >or=50% loss of maximal GAP improvement, occurred in 73% of completers, with a median delay of 14 weeks after the third infusion. No serious adverse event related to the treatment was observed.
  
  
  CONCLUSIONS
  This study confirms, in a large group of severely affected AS patients, the remarkable efficacy of infliximab. Relapse usually occurred after discontinuation of the drug, but almost one-third of completers were still free of relapse 4 months after the last infusion.
authors.affiliation: Institut de Rhumatologie, Hôpital Cochin, Université René Descartes, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Breban
authors.forename: E
authors.initials: E
authors.lastname: Vignon
authors.forename: P
authors.initials: P
authors.lastname: Claudepierre
authors.forename: V
authors.initials: V
authors.lastname: Devauchelle
authors.forename: D
authors.initials: D
authors.lastname: Wendling
authors.forename: E
authors.initials: E
authors.lastname: Lespessailles
authors.forename: L
authors.initials: L
authors.lastname: Euller-Ziegler
authors.forename: J
authors.initials: J
authors.lastname: Sibilia
authors.forename: A
authors.initials: A
authors.lastname: Perdriger
authors.forename: M
authors.initials: M
authors.lastname: Mezières
authors.forename: C
authors.initials: C
authors.lastname: Alexandre
authors.forename: M
authors.initials: M
authors.lastname: Dougados
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011336:Probability; D011446:Prospective Studies; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000175:diagnosis / Q000188:drug therapy*; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000069285:Infliximab